Please provide your email address to receive an email when new articles are posted on . The development of the Xpert MTB/RIF assay has been the most important breakthrough for the diagnosis of ...
Please provide your email address to receive an email when new articles are posted on . An updated version of the Xpert MTB/RIF assay, which includes new gene target ...
In low-incidence, high-resource settings, Xpert Mycobacterium Tuberculosis/Rifampicin Ultra (Xpert MTB/RIF Ultra [Xpert-Ultra]) testing, an automated nucleic acid ...
Tuberculosis (TB) causes more deaths globally than any other infectious disease and is a top 10 cause of death worldwide. Globally in 2017, of the estimated 10 million people with TB, 3.6 million were ...
To honor the World TB Day on Mar 24, 2015, California-based molecular diagnostics provider Cepheid CPHD along with the National Health Laboratory Services (NHLS) of South Africa, recently announced ...
The World Health Organization (WHO) has granted prequalification to the molecular diagnostic test for tuberculosis (TB) called Xpert MTB/RIF Ultra. It is the first test for TB diagnosis and antibiotic ...
Background: The identification of non-tuberculosis (TB) mycobacterial (NTM) infection remains a significant challenge. This study aims to investigate the diagnostic value of multicolour nested ...
Washington, DC - Aug. 29, 2017 - Researchers have demonstrated a new, improved version of the Xpert MTB/RIF assay, a test for Rifampicin-resistance (RIF-R). The Xpert "Ultra" assay overcomes the ...
FDA Expands Xpert MTB/RIF Test Use The Food and Drug Administration (FDA) has granted clearance for the Cepheid Xpert MTB/RIF Assay to help determine if patients with suspected tuberculosis (TB) can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results